Lung cancer, predominantly non-small cell lung cancer (NSCLC), is the leading cause of cancer-related mortality worldwide.
Among immunotherapeutic strategies, the personalized multi-neoepitope vaccine (MNEV) offers a promising approach for managing advanced-stage NSCLC.
